Hand-Assisted Laparoscopic Technique May Reduce Surgery Time in Colon Cancer: New Study Is Underway

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 4
Volume 16
Issue 4

In patients with colorectal cancer, a 'hand-in' approach to laparoscopic surgery—hand-assisted laparoscopic surgery (HALS)—may yield benefits beyond those of traditional laparoscopic techniques, particularly reduced operation time.

NEW YORK—In patients with colorectal cancer, a 'hand-in' approach to laparoscopic surgery—hand-assisted laparoscopic surgery (HALS)—may yield benefits beyond those of traditional laparoscopic techniques, particularly reduced operation time. Patient recruitment to a study assessing HALS vs standard laparoscopic surgery has begun at several sites in New York City.

In a HALS procedure, the surgeon inserts his or her nondominant hand through the hand-assist device and into the intra-abdominal cavity via an incision between 3 and 5 inches in length, and can operate on the patient in conjunction with standard laparoscopic devices held in the dominant hand.

More Rapid Recovery

Similar to advantages of standard laparoscopy over open surgery, HALS has typically been associated with shorter hospital stays, reduced pain, and more rapid recovery, owing in part to the smaller incision required. HALS also has been reported to improve surgical outcome because the intra-abdominal hand provides the surgeon with tactile sensation and 3D spatial orientation, and permits effective and rapid hemostasis. Reports in the literature also suggest the technique can be learned more quickly than standard laparoscopy, with better reproducibility.

GelPort: Newer HALS Device

The second-generation HALS device that will be studied is GelPort (see Figure), made from a soft, gel-like material that maintains an airtight seal around the surgeon's hand while the sleeve and ring apparatus "creates a kind of doorway to the patient's abdomen," explained investigator Jeffrey W. Milsom, MD, DeCosse Distinguished Professor of Surgery and chief of Colon and Rectal Surgery, Weill Medical College of Cornell University.

The GelPort device is inserted through a small pubic-area incision, with the patient under general anesthesia, Dr. Milsom told ONI.

Manufactured by Applied Medical Resources Corporation, of Rancho Santa Margarita, California, the GelPort system consists of a rubber sleeve (wound protector) that passes through the abdominal wall and is attached at one end to a plastic ring, which rests on the outer surface of the patient's skin. An outer gel dome with a central opening is fitted onto the plastic ring, completing the seal.

The surgeon's hand can be passed into and out of the gel without affecting the carbon dioxide seal, or pneumoperitoneum, used to inflate the abdominal cavity for surgery, "giving the surgeon more room during the laparoscopic portion of the procedure," Dr. Milsom said.

Although it is possible to introduce small hand-held instruments through the gel, generally, Dr. Milsom noted, the surgeon inserts other laparoscopic instruments through one or two additional small incisions, "to move the section of affected colon outside the abdomen through the GelPort device—here it becomes a sort of open surgery—and cut away the affected area."

Commenting on the upcoming study, investigator Richard L.Whelan, MD, chief of the Section of Colon and Rectal Surgery, New York-Presbyterian/Columbia University Medical Center, said, "hand-assisted surgery gives surgeons a sense of touch which helps identify the affected area of the colon and helps to better control any bleeding. Also, because the colon is resected outside the abdomen, a sometimes difficult and laborious laparoscopic resection is not necessary. Our study may show that these advantages help cut down on the time of the surgery."

Related Videos
Increasing screening for younger individuals who are at risk of colorectal cancer may help mitigate the rising early incidence of this disease.
Laparoscopy may reduce the degree of pain or length of hospital stay compared with open surgery for patients with colorectal cancer.
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
The toxicity profile of tislelizumab also appears to look better compared with chemotherapy in metastatic esophageal squamous cell carcinoma.